These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1462 related items for PubMed ID: 7559897

  • 21. Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness.
    van den Berghe G, Weekers F, Baxter RC, Wouters P, Iranmanesh A, Bouillon R, Veldhuis JD.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3217-26. PubMed ID: 11443192
    [Abstract] [Full Text] [Related]

  • 22. GH and GHBP activity and not IGF-1 and its receptor activity express growth velocity reduction during treatment of central precocious puberty by a superactive GNRH analogue.
    Eshet R, Silbergeld A, Kauli R, Lazar L, Laron Z.
    Isr J Med Sci; 1994 Aug; 30(8):592-5. PubMed ID: 8045738
    [Abstract] [Full Text] [Related]

  • 23. Serum sex hormone-binding globulin levels in healthy children and girls with precocious puberty before and during gonadotropin-releasing hormone agonist treatment.
    Sørensen K, Andersson AM, Skakkebaek NE, Juul A.
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3189-96. PubMed ID: 17519314
    [Abstract] [Full Text] [Related]

  • 24. Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
    Neely EK, Hintz RL, Parker B, Bachrach LK, Cohen P, Olney R, Wilson DM.
    J Pediatr; 1992 Oct; 121(4):634-40. PubMed ID: 1403402
    [Abstract] [Full Text] [Related]

  • 25. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
    Boguszewski M, Jansson C, Rosberg S, Albertsson-Wikland K.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Serum levels of growth hormone binding protein in children with normal and precocious puberty: relation to age, gender, body composition and gonadal steroids.
    Juul A, Fisker S, Scheike T, Hertel T, Müller J, Orskov H, Skakkebaek NE.
    Clin Endocrinol (Oxf); 2000 Feb; 52(2):165-72. PubMed ID: 10671943
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The effect of long-acting analog of luteinizing hormone-releasing hormone on growth hormone secretory dynamics in children with precocious puberty.
    DiMartino-Nardi J, Wu R, Fishman K, Saenger P.
    J Clin Endocrinol Metab; 1991 Oct; 73(4):902-6. PubMed ID: 1909708
    [Abstract] [Full Text] [Related]

  • 31. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency.
    Juul A, Holm K, Kastrup KW, Pedersen SA, Michaelsen KF, Scheike T, Rasmussen S, Müller J, Skakkebaek NE.
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2497-502. PubMed ID: 9253324
    [Abstract] [Full Text] [Related]

  • 32. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology.
    Heinrichs C, Craen M, Vanderschueren-Lodeweyckx M, Malvaux P, Fawe L, Bourguignon JP.
    Acta Paediatr; 1994 Jun; 83(6):627-33. PubMed ID: 7919761
    [Abstract] [Full Text] [Related]

  • 33. A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation.
    Kamp GA, Mul D, Waelkens JJ, Jansen M, Delemarre-van de Waal HA, Verhoeven-Wind L, Frölich M, Oostdijk W, Wit JM.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2969-75. PubMed ID: 11443153
    [Abstract] [Full Text] [Related]

  • 34. Changes in serum immunoreactive and bioactive growth hormone concentrations in boys with advancing puberty and in response to a 20-hour estradiol infusion.
    Cemeroglu AP, Barkan AL, Kletter GB, Beitins IZ, Foster CM.
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2166-71. PubMed ID: 9215289
    [Abstract] [Full Text] [Related]

  • 35. Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method.
    Kauli R, Galatzer A, Kornreich L, Lazar L, Pertzelan A, Laron Z.
    Horm Res; 1997 Jul; 47(2):54-61. PubMed ID: 9030968
    [Abstract] [Full Text] [Related]

  • 36. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
    Carel JC, Blumberg J, Seymour C, Adamsbaum C, Lahlou N, Triptorelin 3-month CPP Study Group.
    Eur J Endocrinol; 2006 Jan; 154(1):119-24. PubMed ID: 16382000
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone release hormone (D-Tryp6-GnRH) in monthly injections. Its possible use in normal puberty.
    Marcondes JA, Abujamra AC, Minanni SL, Mendonca BB, Nery M, Lerario AC, Pereira MA, Abelin N, Wajchenberg BL.
    Horm Metab Res; 1993 Feb; 25(2):105-9. PubMed ID: 8458605
    [Abstract] [Full Text] [Related]

  • 40. Low growth hormone levels are related to increased body mass index and do not reflect impaired growth in luteinizing hormone-releasing hormone agonist-treated children with precocious puberty.
    Kamp GA, Manasco PK, Barnes KM, Jones J, Rose SR, Hill SC, Cutler GB.
    J Clin Endocrinol Metab; 1991 Feb; 72(2):301-7. PubMed ID: 1991801
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 74.